Clinical Trials Logo
  1. Home
  2. Ovarian Neoplasm
  3. NCT05751629

Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer — COHORT-A  

Ovarian Neoplasm Clinical Trial

Official title:
Cohort A: PARP Inhibitor-Naïve Platinum-Resistant Ovarian Cancer Treatment Cohort With TSR-042, Bevacizumab, and Niraparib

Clinical Trial Summary

The primary objective of this sub study is to evaluate the efficacy of the combination of TSR-042, bevacizumab, and niraparib in participants with advanced, relapsed, high-grade ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 2 prior lines of anticancer therapy, are PARP inhibitor naïve, and have platinum-resistant but not refractory disease. This study is a sub study of the master protocol - OPAL (NCT03574779).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05751629
Study type Interventional
Source Tesaro, Inc.
Contact
Status Completed
Phase Phase 2
Start date November 15, 2018
Completion date April 1, 2022
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Completed NCT01896778 - Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer N/A
Completed NCT03562897 - Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer Phase 2
Completed NCT00248248 - DOXIL for Consolidation Therapy in Ovarian Cancer. Phase 2
Recruiting NCT05960630 - MIRRORS-RCT Pilot: Role of Robotic Interval Cytoreductive Surgery for Advanced Ovarian Cancer N/A
Recruiting NCT05059782 - Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis/Recurrent/Refractory) of Ovarian Cancer N/A
Recruiting NCT05752448 - Survivorship Care for Women Living With Ovarian Cancer: (POSTCARE-O) N/A
Recruiting NCT04906187 - Impact of Specific Monitoring of Intraoperative Analgesia Under General Anesthesia on Chronic Pain After Ovarian Cancer Surgery N/A
Completed NCT01821833 - Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel N/A
Withdrawn NCT01477788 - Prediction of Ovarian Malignancy in the Presence of Sonographic Pelvic Mass N/A
Completed NCT05512676 - Trabectedin/Caelyx vs Cisplatin Hypersensitivity in Relapsed Ovarian Cancer Patients Allergic to Platinum
Completed NCT04898842 - Feasibility Study of a 4 Stage Bowel Obstruction Cancer Diet N/A
Terminated NCT01374685 - Family Communication of Hereditary Breast and Ovarian Cancer Risk Among African Americans
Completed NCT01139957 - Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer
Active, not recruiting NCT05257408 - Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer Phase 3
Completed NCT04573933 - Survival Data and Characteristics of Finisterian Patients Treated With PARP Inhibitors for Ovarian Cancer Between 2014 and 2019.
Terminated NCT02470585 - Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Phase 3
Completed NCT00001898 - Microarray Analysis for Human Genetic Disease N/A
Recruiting NCT04402333 - Minimally Invasive Robotic Surgery, Role in Optimal Debulking Ovarian Cancer, Recovery & Survival
Completed NCT00034281 - Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 Phase 1